| VEGFR | vascular endothelial growth factor receptor | |
| VEGF | vascular endothelial growth factor | |
| BRAF | v-raf murine sarcoma viral oncogene homolog B1 | |
| ETC | electron transport chain | |
| OS | overall survival | |
| PFS | progression-free survival | |
| LKB1 | liver kinase B1 | |
| DNA-PKcs | DNA-dependent protein kinase, catalytic subunit | |
| PI3K | phosphoinositide 3-kinases | |
| Akt | serine-threonine protein kinase | |
| MGMT | O6-alkylguanine DNA alkyltransferase | |
| NLRP3 | nucleotide-binding oligomerization domain-like receptor pyrin domain-containing 3 | |
| FGFR3 | fibroblast growth factor receptor 3 | |
| ARB | adrenergic receptor | |
| ESM-1 | cancer progression-related protein level | |
| PARP | poly (ADP-ribose) polymerase | |
| B-CPAP | poorly differentiated thyroid gland carcinoma | |
| Gli1 | glioma-associated oncogene | |
| Beta-AR | beta-adrenergic receptor | |
| EGFR | endothelial growth factor receptor | |
| Bcl2 | B-cell lymphoma 2 | |
| TNIK | TRAF2- and NCK-interacting protein kinase | |
| AMPK | adenosine monophosphate-activated protein kinase | |
| HMG-CoA | 3-hydroxy-3-methylglutaryl coenzyme A reductase | |
| FDA | US Food and Drug Administration | |
| HER2 | human epidermal growth factor receptor 2 | |
| IGF-I | insulin-like growth factor I | |
| TORC1 | target of rapamycin complex 1 | |
| CSCs | circulating tumor cells | |
| Redd1 | regulated in development and DNA damage responses 1 | |
| mTOR | mammalian target of rapamycin | |
| NF-κB | nuclear factor kappa B | |
| GSDMD | gasdermin D | |
| OCT3/4 | octamer-binding transcription factor | |
| COX-2 | cyclooxygenase-2 | |
| IL-6 | interleukin 6 | |
| CSS | cancer-specific survival | |
| Stat3 | signal transducer and activator of transcription 3 | |
| ER | estrogen receptor | |
| DUSP1 | dual specificity phosphatase 1 | |
| OxPhos | oxidative phosphorylation | |
| MSH2 | MutS Homolog 2 protein-coding gene | |